Skip to main content

Table 9 Advances of MEK-TKIs

From: Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Drug

Brand name

Manufacturer

Targets

Applications of diseases

Approved years

Trametinib

Mekinist

GlaxoSmithKline

MEK1/2

Unresectable or metastatic BRAF V600E/K + melanoma

2013 [153]

Combined with dabrafenib for the same condition above

2014 [154]

Combined with dabrafenib for metastatic BRAF V600E + NSCLC who received previous treatment with chemotherapy

2017

Combined with dabrafenib for locally advanced or metastatic BRAF V600E + ATC with no locoregional treatment options

2018 [155]

Cobimetinib

Cotellic

Genentech Inc

MEK1/2

Combined with vemurafenib for BRAF V600E/K + advanced or unresectable melanoma

2015 [156]

Binimetinib

Mektovi

Array BioPharma Inc

MEK1/2

Combined with encorafenib for unresectable or metastatic BRAF V600E/K + melanoma

2018 [157]

Selumetinib

Koselugo

AstraZeneca and Merck

MEK1/2

Pediatric patients (≥ 2 years old) with symptomatic, inoperable NF1 plexiform neurofibromas

2020 [158]

  1. In the last column, the four drugs were firstly approved by Food and Drug Administration (FDA)
  2. ATC anaplastic thyroid cancer, NF1 neurofibromatosis type 1
  3. Data source: www.fda.govwww.drugs.com